Abstract Number: 0268 • ACR Convergence 2021
Effect of Biologic Agents on Lipids and Cardiovascular Risk in Rheumatoid Arthritis Patients
Background/Purpose: Cardiovascular disease (CVD) risk scores incorporating measures of inflammation such as the Reynolds risk score (RRS) may be appropriate to predict CVD risk in…Abstract Number: 0867 • ACR Convergence 2021
A Proteomic/Transcriptomic Analysis Associates with Subclinical Vascular Disease in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with enhanced cardiovascular (CV) risk linked to both traditional Framingham risk factors and lupus-specific immune dysregulation. Characterizing an…Abstract Number: 1126 • ACR Convergence 2021
Synovial Cell Dysfunction in Obese Patients May Contribute to Poor Outcomes in Knee Osteoarthritis
Background/Purpose: Obesity is a major risk factor for poor outcomes in knee osteoarthritis (OA) and may involve both mechanical and physiological stresses on joint tissues.…Abstract Number: 1578 • ACR Convergence 2021
NLRP3 Inflammasome Pathway Expression at Atheroma Plaques from Peripheral Artery Disease According to the Uricemic Status
Background/Purpose: Both hyperuricemia and monosodium urate crystals induce persistent inflammation. In vitro, soluble urate can prime innate immune cells and promote NLRP3 inflammasome activation and…Abstract Number: 0274 • ACR Convergence 2021
Angiopoietin-Like Protein 4, Apolipoprotein C3 and Lipoprotein Lipase Axis in the Abnormal Lipid Profile of Patients with Rheumatoid Arthritis: Relation to Subclinical Atheromatosis
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increase in cardiovascular (CV) risk, attributed, among other factors, to the existence of an abnormal lipid profile.…Abstract Number: 0916 • ACR Convergence 2021
Disease Activity and Inflammation in Axial Spondyloarthritis Patients Who Did Not Experience Flares Following Certolizumab Pegol Withdrawal, Dose Reduction or Dose Continuation
Background/Purpose: C-OPTIMISE was a phase 3b study investigating certolizumab pegol (CZP) maintenance dose continuation, reduction or withdrawal following achievement of sustained remission in patients with…Abstract Number: 1196 • ACR Convergence 2021
Morning Stiffness Already Associates with Systemic Inflammation and Subclinical Joint Inflammation in the Pre-RA Phase of Arthralgia
Background/Purpose: Morning stiffness (MS) is characteristic for Rheumatoid Arthritis (RA) and associates with markers of systemic and local inflammation in RA-patients. In patients with arthralgia,…Abstract Number: 1625 • ACR Convergence 2021
Clinical Characteristics of Multisystem Inflammatory Syndrome in Children: A Provincial Cohort
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a post-infectious complication of COVID-19 infection with overlapping features of Kawasaki Disease (KD) and Toxic Shock Syndrome…Abstract Number: 0013 • ACR Convergence 2021
Cyclin Dependent Kinase 4 and 6 Determine the Cytokine Responsiveness by Stabilizing JUN in Rheumatoid Arthritis Synovial Fibroblasts
Background/Purpose: Although current inflammation-targeted therapy improved the outcome of patients with rheumatoid arthritis (RA), the achievement of complete disease remission was still challenging. Since synovial…Abstract Number: 0284 • ACR Convergence 2021
Risk Factors for Dementia in Patients with Incident Rheumatoid Arthritis: A Population-based Cohort Study
Background/Purpose: Growing evidence from observational studies suggests that patients with rheumatoid arthritis (RA) are at increased risk for cognitive impairment and dementia. Longitudinal population-based studies…Abstract Number: 0921 • ACR Convergence 2021
Effect of Secukinumab on Radiographic Progression and Inflammation in Sacroiliac Joints and Spine in Patients with Non-radiographic Axial Spondyloarthritis: 2-year Imaging Outcomes from a Phase III Randomized Trial
Background/Purpose: Axial spondyloarthritis (axSpA) is characterized by inflammation of the sacroiliac joints (SIJ) and the spine. Secukinumab (SEC) treatment was clinically efficacious and reduced SIJ…Abstract Number: 1216 • ACR Convergence 2021
Evidence of a Tendency for Localized Recurrence of Arthritis in Rheumatoid Arthritis Patients
Background/Purpose: Local inflammation may cause synovial fibroblasts to become sensitized, resulting in higher susceptibility to arthritis. Longitudinal assessment of joint involvement in rheumatoid arthritis (RA)…Abstract Number: 1640 • ACR Convergence 2021
Multisystem Inflammatory Syndrome in Children at Two Tertiary Hospitals in Cape Town, South Africa: Clinical Phenotype and Distinguishing Features from Similar Acute Inflammatory Conditions
Background/Purpose: Distinguishing Multisystem Inflammatory Syndrome in Children (MIS-C) associated with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) from acute, pyrexial childhood illness can be challenging.…Abstract Number: 0016 • ACR Convergence 2021
Structural and Functional Neurobiological Alterations of Salience and Sensorimotor Networks in Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a common childhood illness, characterized by inflammation of the joint, chronic pain and decreased physical functioning. To date, the…Abstract Number: 0322 • ACR Convergence 2021
Histopathological Changes in Parotid and Labial Salivary Gland Tissue in Primary Sjögren’s Syndrome Patients After Abatacept Treatment
Background/Purpose: In a previous open-label phase II study, we showed that abatacept treatment might inhibit local formation of autoreactive memory B cells in parotid glands…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 58
- Next Page »